Summary:
The study will evaluate the efficacy and safety of ITI-007 adjunctive in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The trial may take up to 6 weeks.
Qualified Participants Must:
• Be between 18 and 65 years of age (Adult)
•
Be experiencing a current major depressive episode
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.